ENTX Company Profile and Key Details

Entera Bio Ltd. generated EPS of -$0.24 over the past year. Five-year average earnings growth is 22.19%. The latest quarter delivered EPS of $0.07. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$134.38. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $9.00. The high target offers 488.24% upside. The low target suggests 429.41% downside. The mean target is $9.50. This offers 458.82% upside. Entera Bio Ltd. earnings surprise history is frequent misses against expectations. The quarter that ended May 08, 2026, missed forecasts by -187.5%. The prior quarter beat by -22.22%. Over the last six quarters, Apple has recorded several small beats. These include -25.0% in March 28, 2025.

Entera Bio Ltd. has 45.66 million shares outstanding. The public float is 28.77 million shares, elevated short interest at 0.14% of float. This equals 55.48 thousand shares. The short ratio is 0.23 days. Institutional investors hold 29.54% of the float. Insiders own 24.31%. Schwartz Phillip holds 607.41 thousand shares, Toledano Miranda Jayne has 426.58 thousand shares and Ellis Sean has 188.10 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

ENTX has shown mixed momentum, losing 0.0% over the past week and -33.19% over the past quarter, though year-to-date performance is down -19.07%. Short-term trend indicators are bullishly aligned (SMA20 7.09%, SMA50 -5.23%, SMA200 -23.98%). The stock’s 14-day RSI is 50.1 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -53.11% below its high and over 51.0% above its low. Average 10-day trading volume of 310.01 thousand shares is below the 3-month average of 1.08 million, indicating normal recent market interest.

Entera Bio Ltd. (NASDAQ:ENTX) closed at $1.70 USD, gaining $0.01 (0.59%) from the previous close of $1.69. The stock is currently mid-range between its 52-week high and low $0.91 and $3.22. With a market capitalization of about $83.79 million, Entera Bio Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.43). Key stats such as the average daily volume over the past year has been around 1.05 million shares, volume is running light vs its 52-week average. Headquartered in Jerusalem, JM, Entera Bio Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Miranda J. Toledano, the company employs approximately 22 people and listed since June 28, 2018. Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments.

Entera Bio Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.14. This means the shares are trading above this model’s fair value.

Entera Bio Ltd. trades at a P/E ratio of -6.53, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.69 trading at moderately above to book value. The P/FCF stands at -8.84, also above market averages.

Our AI price prediction model suggests that Entera Bio Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 20.59%, with price expected at $2.05 by July 22, 2026, within a range of $1.97 to $2.13 3-Month Outlook: Projected rise of 54.71%, reaching $2.63 by October 06, 2026, with a range of $2.44 to $2.79. 1-Year Outlook: Projected gain of 82.35%, with price at $3.10 by July 08, 2027, within a range of $0.00 to $0.10.

Entera Bio Ltd. (NASDAQ:ENTX) shares are down -19.07% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Entera Bio Ltd. trading at a premium to the broader market with a P/E of -6.53. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.07, suggesting 492.35% upside. Our AI forecast model points to short-term strength (20.59% over two weeks), a medium-term rise (54.71% over three months), and a longer-term gain (82.35% over one year), with expected trading ranges indicating moderate volatility.